Skip to main content

Table 4 The relationship between TD and efficacy of Peg-IFNα

From: Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha

 

Hyperthyroidism/subclinical hyperthyroidism

Hypothyroidism/subclinical hypothyroidism

p value

HBsAg seroclearance rate in 24 weeks

12.9% (8/62)

7% (3/43)

0.525

Rate of decreasing in HBsAg levels > 1log in 24 weeks

40.7% (22/54)

15% (6/40)

0.007

HBeAg seroclearance rate in 24 weeks

21.7% (5/23)

31.6% (6/19)

0.712

HBsAg seroclearance rate in 48 weeks

37.9% (11/29)

5.7% (2/35)

0.001

Rate of decreasing in HBsAg levels > 1log in 48 weeks

52.6% (10/19)

27.2% (9/33)

0.067

HBeAg seroclearance rate in 48 weeks

55.5% (5/9)

47.4% (9/19)

1

  1. TD thyroid disorders, Peg-IFNα pegylated-interferon alpha, HBsAg hepatitis B surface antigen